新天药业(002873) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the current period was CNY 201,781,886.88, a slight increase of 0.69% year-on-year[8] - Net profit attributable to shareholders was CNY 32,126,642.90, reflecting a marginal increase of 0.04% year-on-year[8] - Basic earnings per share decreased by 31.81% to CNY 0.3179 compared to the same period last year[8] - The net profit attributable to shareholders for 2018 is expected to range from ¥69,422,686.26 to ¥79,340,212.87, reflecting a growth of 5.00% to 20.00%[19] - The company reported a 2212.13% increase in investment income to ¥3,005,774.47 from financial products[17] Assets and Liabilities - Total assets increased by 16.09% to CNY 994,236,389.98 compared to the end of the previous year[8] - Net assets attributable to shareholders increased by 8.16% to CNY 672,858,191.14 compared to the end of the previous year[8] - The company's cash and cash equivalents increased by 42.06% to ¥122,883,735.80 due to new short-term borrowings[16] - Short-term borrowings increased by 48.92% to ¥207,000,000.00 due to new bank loans[16] Cash Flow - Net cash flow from operating activities was CNY 36,746,112.42, an increase of 4.59% year-on-year[8] - The cash flow from investing activities improved by 39.77% compared to the previous year, amounting to -¥58,740,759.79[17] Shareholder Information - The total number of common shareholders at the end of the reporting period was 11,970[12] - The largest shareholder, Guiyang Xintian Biotechnology Development Co., Ltd., held 44.04% of the shares[12] Expenses - Research and development expenses rose by 66.50% to ¥26,565,227.37 as a result of increased R&D activities[16] - The company's management expenses increased by 52.07% to ¥62,950,092.18 due to the establishment of a new academic department[16] Other Financial Information - Non-recurring gains and losses totaled CNY 4,130,106.94 for the year-to-date[9] - The company has no overdue commitments from shareholders or related parties during the reporting period[18] - The total amount of entrusted financial management reached ¥14,000,000, with no overdue amounts[26] - Prepayments surged by 203.75% to ¥21,958,068.86 primarily due to land acquisition payments[16] - The weighted average return on equity was 4.79%, down by 0.61% compared to the same period last year[8]